Solid doses first patient on Phase 3 trial

Today, Solid Biosciences announced that the first participant has been dosed in the Phase 3 Impact Duchenne clinical trial, a randomised, double-blind, placebo-controlled study evaluating SGT-003 for Duchenne. Clinical trial sites are currently active in Australia and...

Solid announces positive clinical update

Solid Biosciences has announced a positive clinical update on the SGT-003 gene therapy programme. This update includes interim safety and biomarker data from the ongoing Phase 1/2 Inspire Duchenne clinical trial. To date, 40 participants have been dosed with SGT-003...

Solid shares update on Inspire Duchenne clinical trial

Solid Biosciences has released an update on its Inspire Duchenne clinical trial, which is investigating the safety, tolerability and efficacy of its gene therapy candidate SGT-003. The Phase 1/2, open-label study has now dosed 23 patients, and expects to have dosed 30...

Update on gene therapy Elevidys

Earlier this month the US Food and Drug Administration (FDA) requested that Sarepta Therapeutics place Elevidys clinical trials on hold, due to safety concerns. The request followed three deaths potentially related to the gene therapy products. The deaths appeared to...

Solid reports positive clinical trial data

Solid Biosciences has shared positive clinical data for the first three patients in its Inspire Duchenne clinical trial. They have been dosed with Solid’s next generation gene therapy, known as SGT-003. Biopsy data at day 90 showed average microdystophin...

Solid expands gene therapy trial

We are pleased to share that Solid Biosciences has seen encouraging early results so far in the clinical trial of its next-generation gene therapy, SGT-003. The study, called Inspire Duchenne, began earlier this year at two sites in the US, and has already expanded to...

World Muscle Society awards 2024 DRF prize

The World Muscle Society has awarded the Duchenne Research Fund prize at the annual WMS international congress, supporting a talented researcher in the Duchenne arena. The winner at the 29th congress in Prague, Czech Republic, in October 2024 was Rebecca Willcocks,...

Solid begins dosing next-generation gene therapy

We are pleased to share that Solid Biosciences has begun dosing patients in the Phase I/II clinical study of its next-generation gene therapy, SGT-003. The study, INSPIRE DUCHENNE, is ongoing at two sites in the US – Nationwide Children’s Hospital in Columbus, Ohio,...

FDA expands approval for gene therapy Elevidys

The US Food and Drug Adminisatration has announced it has expanded the approval of Sarepta Therapeutics’ gene therapy, known as Elevidys, for the treatment of ambulatory and non-ambulatory people with Duchenne aged 4 and over. In June last year we shared that...

Pfizer provides update on gene therapy trial

Pfizer has announced that its mini-dystrophin gene therapy has not met its primary or secondary endpoints. Click here to read Pfizer’s update on Phase 3 of CIFFREO, a randomised double-blind placebo-controlled study in ambulatory boys aged 4-7. The primary...